Study reports combined time-restricted feeding and resistance training enhance tirzepatide outcomes in obese female mice

A preclinical study shows that combining tirzepatide with time-restricted feeding and resistance training accelerates weight loss, improves insulin sensitivity, and preserves skeletal muscle mass in obese female mice.

Researchers at the University of Campinas and the University of São Paulo evaluated the effects of tirzepatide alone and in combination with time-restricted feeding (TRF) and resistance training in obese female Swiss mice.

Following a 10-week obesity induction period, the mice underwent an 8-week intervention involving subcutaneous dose-escalating tirzepatide, a 12-hour TRF window, and/or resistance training via stair climbing.

The researchers reported that combining tirzepatide with TRF and resistance training accelerated weight loss and reduced adipocyte hypertrophy compared to isolated treatments.

The addition of resistance training to tirzepatide therapy preserved skeletal muscle mass, improved strength performance, and enhanced systemic insulin sensitivity.

All evaluated interventions reduced hepatic lipid accumulation and lipogenic gene expression, though the combination therapies did not provide additional hepatic benefits over tirzepatide alone.

Skeletal muscle loss is a major therapeutic limitation associated with rapid weight loss induced by GLP-1 and GIP receptor agonists.

These findings provide preclinical proof-of-concept that structured physical and dietary timing interventions can counteract muscle wasting while synergistically enhancing the metabolic and weight-loss efficacy of dual-agonist therapies.

The results highlight the potential for clinicians and therapeutic developers to design multi-modal regimens that pair pharmacotherapy with non-pharmacological interventions to achieve healthier body composition outcomes.

Developing protocols that actively preserve muscle mass during metabolic therapy addressing obesity directly supports healthspan-focused clinical outcomes, targeting a key concern of the longevity and metabolic therapeutics market.

Clinical studies translating these findings to human cohorts to determine if combining GIP/GLP-1 receptor agonists with structured resistance training and time-restricted eating successfully mitigates muscle loss in patients.